Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trialBruce Cree, Piotr Sokolowski, Gary Cutter et al.|The Lancet Neurology|2020Cited by 104
Smoking cessation and outcome after ischemic stroke or TIAKatherine A. Epstein, Andreas Hetzel, Brett Gerstenhaber et al.|Neurology|2017Cited by 94
Expert opinion on the long-term use of cladribine tablets for multiple sclerosis: Systematic literature review of real-world evidenceCelia Oreja‐Guevara, Bassem Yamout, Wallace Brownlee et al.|Multiple Sclerosis and Related Disorders|2022Cited by 44